We build the exact model your study needs.

Designed and delivered by ingenious targeting laboratory. Quote in 24 hours.

Get a Quote
Skip to main content
Uncertain NIH funding? Start now, pay later.

READY TO SHIP!

LIVE · SPERM · EMBRYO

Catalog Models

PDL1 Humanized Mouse Models

PDL1 humanized mice enable preclinical testing of anti human PDL1 therapeutic antibodies including atezolizumab, durvalumab, and avelumab in immunocompetent mouse systems.

Order catalog modelSearch All ModelsRequest a Quote

Ready catalog models

ModelTypeStatusCatalog
hPD-L1
The endogenous mouse Cd274(also known as PD-L1) gene was replaced by human PD-L1 gene . While hPD-L1(2)(Stock No.HU 190039) mice function similarly to hPD-L1 mice,for more detailed information please contact our technical advisor.
HULIVEHU 00062Inquire
hPD-L1(2)/hCCR8
hPD-1(2)(HU 190039) was crossed with hCCR8(HU 190053) to generate hPD-L1(2)/hCCR8 mice.
HUEMBRYOHU 210401Inquire
hPD-L1(2)/hCD28
hPD-L1(2)(HU 190039) was crossed with hCD28(HU 190011）to generate hPD-L1(2)/hCD28 mice
HUEMBRYOHU 210370Inquire
hPD-L1(BALB/c)
The hPD-L1(E3-4)(HU 190039) mice were backcrossed to BALB/c genetic background, to create the new strain of hPD-L1(BALB/c) (HU 220028) mice.
HULIVEHU 220028Inquire
hPD-L1(E3-4)
Extracellular domain of mouse Cd274(also known as PD-L1) gene was replaced by human PD-L1 gene. While hPD-L1(Stock No.HU 00062) mice function similarly to hPD-L1(2) mice,for more detailed information please contact our technical advisor.
HUEMBRYOHU 190039Inquire
hPD-L1/h4-1BB(2)
hPD-L1(HU 00062) was crossed with h4-1BB(2)(HU 190077) to generate hPD-L1/h4-1BB(2).
HUEMBRYOHU 200260Inquire
hPD-L1/hCD27(2)
hPD-L1(HU 00062) was crossed with hCD27(2)(HU 190035)to generate hPD-L1/hCD27(2) mice.While hPD-L1/hCD27 (Stock No.HU 18023) have been pulled from shelves for some reasons.
HUEMBRYOHU 200274Inquire
hPD-L1/hCD28
hPD-L1(HU 00062) was crossed with hCD28(HU 190011) to generate hPD-L1/hCD28 mice
HUEMBRYOHU 210019Inquire
hPD-L1/hCD40
hPD-L1(HU 00062) was crossed with hCD40(HU 00076) to generate hPD-L1/hCD40.
HUEMBRYOHU 18024Inquire
hPD-L1/hCD73(2)
hPD-L1(HU 00062) was crossed with hCD73(2)(HU 200009) to generate hPD-L1/hCD73(2) mice.
HUEMBRYOHU 210356Inquire
hPD-L1/hCTLA-4
hPD-L1(HU 00062) was crossed with hCTLA4(HU 00014)to generate hPD-1/hCTLA4 mice
HUEMBRYOHU 00102Inquire
hPD-L1/hLAG3
hPD-L1（HU 00062）was crossed with hLAG3（HU 00049）to generate hPD-L1/hLAG3.
HUEMBRYOHU 00137Inquire
hPD-L1/hOX40
hPD-L1（HU 00062）was crossed with hOX40（HU 00041）to generate hPD-L1/hOX40.
HUEMBRYOHU 00111Inquire
hPD-L1/hSEMA4D
hPD-L1(HU 00062) was crossed with hSEMA4D(HU 00117) to generate hPD-L1/hSEMA4D.
HUEMBRYOHU 190034Inquire
hPD-L1/hSIGLEC15
hPD-L1(HU 00062) was crossed with hSIGLEC15(HU 190037) to generate hPD-L1/hSIGLEC15.
HUEMBRYOHU 2000103Inquire
hPD-L1/hSIRPA(2)
hPD-L1(HU 00062) was crossed with hSIRPA(2)(HU 18015) to generate hPD-L1/hSIRPA(2).
HUEMBRYOHU 2000099Inquire
hPD-L1/hSTING
hPD-L1(HU 00062) was crossed with hSTING(HU 190036) to generate hPD-L1/hSTING.
HUEMBRYOHU 2000105Inquire
hPD-L1/hTIGIT
hPD-L1(HU 00062) was crossed with hTIGIT(HU 00053) to generate hPD-L1/hTIGIT.
HUEMBRYOHU 18013Inquire
hPD-L1/hTIM3
hPD-L1(HU 00062) was crossed with hTIM3(HU 00054) to generate hPD-L1/hTIM3.
HUEMBRYOHU 190056Inquire
hPD-L1/hVEGFA
The hVEGFA (HU 2000028) was crossed with hPD-L1(HU 00062) to generate hVEGFA/hPD-L1 mice.
XASPERMXA 252262Inquire
hPD-L1/hVEGFR2
hPD-L1(HU 00062) was crossed with hKDR(HU 00098) to generate hPD-L1/hKDR.
HUEMBRYOHU 2000102Inquire
hPD-L1/hVISTA
hPD-L1(HU 00062) was crossed with hVISTA(HU 00118) to generate hPD-L1/hVISTA.
HUEMBRYOHU 2000094Inquire

Search Our Catalog Models

Explore 14,774+ genetically engineered mouse and rat models

14,774+
Total Models
5,000+
Unique Genes
2,400+
Live Models
7,700+
Sperm Cryo
3,100+
Embryo Cryo
6+
Model Types

Why Humanize PDL1

Species Specificity of Therapeutic Antibodies

Anti PDL1 therapeutic antibodies are engineered specifically for human PDL1:

  • Antibody epitopes designed against human CD274 sequence
  • Limited cross reactivity with mouse PDL1
  • Cannot evaluate efficacy in wildtype mice
  • Humanized models enable testing of clinical candidates

PDL1 humanization provides the human target necessary for evaluating anti PDL1 therapeutics.

PDL1 Expression Biology

PDL1 is expressed on multiple cell types relevant to tumor immunity:

  • Tumor cells: Direct expression for immune evasion
  • Dendritic cells: Regulation of T cell priming
  • Macrophages: Tumor associated macrophage function
  • Other immune cells: Broad immune regulation

Humanized PDL1 in all expressing cell types enables comprehensive evaluation of anti PDL1 effects across the tumor microenvironment.

Translational Relevance

Humanized models improve translation to clinical outcomes:

  • Test the actual clinical candidate
  • Evaluate on target effects with human protein engagement
  • Assess PDL1 expression and blocking in tumor tissue
  • Support biomarker development with human specific reagents

Humanization Strategies

Extracellular Domain Humanization

Replace the mouse PDL1 extracellular domain with human sequence:

Human extracellular domain provides antibody binding epitopes
Mouse transmembrane and intracellular domains preserved
Normal downstream signaling maintained
Compatibility with mouse immune system

Extracellular domain humanization is optimal for therapeutic antibody testing where antibody binding to the surface exposed protein is the primary consideration.

Complete Gene Humanization

Full replacement of mouse Cd274 with human CD274:

Complete human PDL1 protein sequence
Human specific expression characteristics
Study human PDL1 biology comprehensively
Appropriate for mechanistic studies beyond antibody testing

Considerations for PDL1 Humanization

PDL1 humanization has specific considerations:

PDL1 expressed on host immune cells and tumor cells
Syngeneic tumors continue to express mouse PDL1
For complete humanization of tumor PDL1, consider human PDL1 expressing tumor cell lines
Host humanization sufficient for many applications

Applications

Anti PDL1 Antibody Efficacy Testing

Primary application for PDL1 humanized mice:

  • Test atezolizumab, durvalumab, avelumab, and other clinical antibodies
  • Evaluate novel anti PDL1 candidates
  • Compare antibody characteristics and potency
  • Assess ADCC and other Fc effector contributions

Combination Immunotherapy

PDL1 humanized mice support combination studies:

  • Anti PDL1 plus chemotherapy
  • Anti PDL1 plus targeted therapy
  • Anti PDL1 plus radiation
  • Anti PDL1 plus anti PD1 (dual humanized models for mechanistic studies)

Tumor Model Compatibility

PDL1 humanized mice on C57BL/6 background work with common syngeneic models. Note that syngeneic tumors express mouse PDL1. Host PDL1 humanization enables testing of antibody effects on host immune and stromal cell PDL1, which is often the predominant effect in checkpoint blockade.

PDL1 as Biomarker

Humanized models support PDL1 biomarker studies:

  • Test clinical grade anti human PDL1 diagnostic antibodies
  • Evaluate PDL1 expression scoring in humanized tissues
  • Develop companion diagnostic approaches
  • Correlate PDL1 expression with response

Tumor Model Compatibility

Tumor ModelTumor TypePDL1 Expression
MC38Colon carcinomaModerate to high
B16MelanomaVariable
LLCLung carcinomaVariable
E0771Breast carcinomaModerate

PDL1 vs PD1 Humanization

FactorPDL1 HumanizationPD1 Humanization
TargetLigand on tumor/APCReceptor on T cells
ExpressionTumor, DC, macrophagesActivated T cells
Antibody targetsAtezolizumab, durvalumabPembrolizumab, nivolumab
MechanismBlock ligandBlock receptor

Dual PD1/PDL1 Humanization

For comprehensive PD1/PDL1 axis studies, both targets can be humanized:

Complete humanization of checkpoint axis
Test PD1 and PDL1 antibodies in same model
Mechanistic studies of pathway biology
Combination PD1 + PDL1 blocking approaches
PD1 Humanized MiceCTLA4 Humanized Mice

Combination Models

CombinationApplications
PDL1 + PD1Complete PD1/PDL1 axis humanization
PDL1 + CTLA4Dual checkpoint combinations
PDL1 + LAG3Novel combination strategies
PDL1 + TIGITEmerging checkpoint combinations

Multi humanized models enable comprehensive evaluation of combination checkpoint blockade using clinical antibodies.

Technical Considerations

Strain Background

Choose strain background based on experimental requirements:

  • C57BL/6: Compatible with MC38, B16, LLC, E0771
  • BALB/c: Compatible with CT26, 4T1, EMT6

Functional Validation

Validate humanized PDL1 function in your experimental system:

  • Confirm human PDL1 surface expression
  • Verify therapeutic antibody binding
  • Test functional checkpoint blockade
  • Assess PDL1 expression on relevant cell types

Selected Publications

Humanized checkpoint models generated by ingenious targeting laboratory have supported immuno oncology research:

Reinartz DM, Escamilla-Rivera V, Shao M, Tribble SL, Caulin C, Wilson JE. 2025. Impact of absent in melanoma 2 on head and neck squamous cell carcinoma development J Immunol. 12(214): 3565-3578 ↗

Hockemeyer K, Sakellaropoulos T, Chen X, Ivashkiv O, Sirenko M, Zhou H, Gambi G, Battistello E, Avrampou K, Sun Z, Guillamot M, Chiriboga L, Jour G, Dolgalev I, Corrigan, K, Bhatt, Osman I, Tsirigos A, Kourtis N, Aifantis I. 2024. The stress response regulator HSF1 modulates natural killer cell anti-tumour immunity Nat Cell Bio 26(10): 1734-1744 ↗

View All Publications

What Researchers Say

“ingenious targeting laboratory produced a new conditional mouse model for us and the quality of service was exceptional. The team is extremely knowledgeable and the work was completed at the highest possible standards. My project manager was excellent and always happy to answer technical questions and keep me up to date with progress and potential problems. I would recommend ingenious targeting laboratory highly and will use them again in the future if I need to generate a new mouse line.”

— Albert Basson, PhD

King's College London

View All Testimonials→

Frequently Asked Questions

Other Humanized Checkpoint Models

Related Model Types

Project Resources